Upadacitinib for Immune Checkpoint Inhibitor–Related Dermatitis: A Nonrandomized Clinical Trial
-
By
-
Chengshui Chen
-
Xinyu Liang
-
Zheng Peng
-
Yan Zou
-
Huijuan He
-
Xiaoyan Zhang
-
Yi He
-
Shixiu Wu
-
May 1, 2026
-
Objective:
To evaluate the resolution rate of severe ICI-related dermatitis in patients with solid tumors treated with upadacitinib.
Key Findings:
- 100% resolution rate of dermatitis at day 28 (95% CI, 89%-100%).
- Significant rash relief reported by all patients, with 93.9% continuing ICI treatment.
- Common adverse event was creatine kinase elevation in 15.2% of patients, with no serious AEs.
Interpretation:
Upadacitinib shows rapid efficacy in treating ICI-related dermatitis with fewer adverse events compared to traditional corticosteroid treatments.
Limitations:
- Single-group design limits randomized control.
- Small sample size.
- Lack of long-term follow-up.
Conclusion:
Upadacitinib could be a potential therapeutic option for managing ICI-related dermatitis, warranting future randomized clinical trials.
